ALZAMEND NEURO, INC. Net Income (Loss) Attributable to Parent, Diluted
ALZAMEND NEURO, INC. (ALZN) reported Net Income (Loss) Attributable to Parent, Diluted of -$2.20 million for the 3-month period ending 2026-01-31, per its 10-Q filed 2026-03-11.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAttributableToParentDiluted · last filed 2026-03-11
- ALZAMEND NEURO, INC. net income (loss) attributable to parent, diluted for the quarter ending 2026-01-31 was -$2.20M.
- ALZAMEND NEURO, INC. net income (loss) attributable to parent, diluted for the quarter ending 2025-10-31 was -$1.00M.
- ALZAMEND NEURO, INC. net income (loss) attributable to parent, diluted for the quarter ending 2025-01-31 was -$1.04M.
- ALZAMEND NEURO, INC. net income (loss) attributable to parent, diluted for the quarter ending 2024-10-31 was -$1.42M.
| Period end | Net Income (Loss) Attributable to Parent, Diluted 3 month | Net Income (Loss) Attributable to Parent, Diluted 6 month | Net Income (Loss) Attributable to Parent, Diluted 9 month |
|---|---|---|---|
| 2026-01-31 | -$2.20M 10-Q · filed 2026-03-11 | -$3.20M derived: sum of 2 quarters · filed 2026-03-11 | -$5.90M 10-Q · filed 2026-03-11 |
| 2025-10-31 | -$1.00M 10-Q · filed 2025-12-09 | -$3.70M 10-Q · filed 2025-12-09 | |
| 2025-01-31 | -$1.04M 10-Q · filed 2026-03-11 | -$2.45M derived: sum of 2 quarters · filed 2026-03-11 | -$3.38M 10-Q · filed 2026-03-11 |
| 2024-10-31 | -$1.42M 10-Q · filed 2025-12-09 | -$2.39M 10-Q · filed 2025-12-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Medicus Pharma Ltd. (MDCX) | $0.010B |